Abstract:DNA methyltransferase 3A (DNMT3A) is an enzyme involved in DNA methylation that is frequently mutated in human hematologic malignancies. We have previously shown that inactivation of Dnmt3a in hematopoietic cells results in chronic lymphocytic leukemia in mice. Here we show that 12% of Dnmt3a-deficient mice develop CD8+ mature peripheral T cell lymphomas (PTCL) and 29% of mice are affected by both diseases. 10% of Dnmt3a+/- mice develop lymphomas, suggesting that Dnmt3a is a haploinsufficient tumor suppressor in PTCL. DNA methylation was deregulated genome-wide with 10-fold more hypo- than hypermethylated promoters and enhancers, demonstrating that hypomethylation is a major event in the development of PTCL. Hypomethylated promoters were enriched for binding sites of transcription factors AML1, NF-κB and OCT1, implying the transcription factors potential involvement in Dnmt3a-associated methylation. Whereas 71 hypomethylated genes showed an increased expression in PTCL, only 3 hypermethylated genes were silenced, suggesting that cancer-specific hypomethylation has broader effects on the transcriptome of cancer cells than hypermethylation. Interestingly, transcriptomes of Dnmt3a+/- and Dnmt3aΔ/Δ lymphomas were largely conserved and significantly overlapped with those of human tumors. Importantly, we observed downregulation of tumor suppressor p53 in Dnmt3a+/- and Dnmt3aΔ/Δ lymphomas as well as in pre-tumor thymocytes from 9 months old but not 6 weeks old Dnmt3a+/- tumor-free mice, suggesting that p53 downregulation is chronologically an intermediate event in tumorigenesis. Decrease in p53 is likely an important event in tumorigenesis because its overexpression inhibited proliferation in mouse PTCL cell lines, suggesting that low levels of p53 are important for tumor maintenance. Altogether, our data link the haploinsufficient tumor suppressor function of Dnmt3a in the prevention of mouse mature CD8+ PTCL indirectly to a bona fide tumor suppressor of T cell malignancies p53.

Lysine methyltransferase Kmt2d regulates naive CD8+ T cell activation-induced survival

KMT2D Histone Methyltransferase Modulates Chromatin Accessibility During Regulatory T Cell Development (LYM6P.714)

Histone Demethylases UTX and JMJD3 Are Required for NKT Cell Development in Mice

KMT2D regulates activation, localization, and integrin expression by T-cells

Regulation of Activated Cd4(+) T Cells by Nk Cells Via the Qa-1-Nkg2a Inhibitory Pathway

KMT2D Deficiency Promotes Myeloid Leukemias which Is Vulnerable to Ribosome Biogenesis Inhibition

Enhanced Anti-Tumor Response Upon Deficiency of Msn Kinase MINK1 in Mice

Definition of a Qa-1-Qdm-dependent Interaction Between NK Cells and Activated T Cells That Inhibits Expansion and Memory Development of Pathogenic T Cells (88.31)

DNA demethylase Tet2 promotes the terminal maturation of natural killer cells

Dnmt3a Is a Haploinsufficient Tumor Suppressor in CD8+ Peripheral T Cell Lymphoma

An early, novel arginine methylation of KCa3.1 attenuates subsequent T cell exhaustion.

Histone methyltransferase KMT2D contributes to the protection of myocardial ischemic injury

The histone demethylase Kdm6b regulates the maturation and cytotoxicity of TCRαβ+CD8αα+ intestinal intraepithelial lymphocytes

KMT1E-mediated Chromatin Modifications at the FcγRIIb Promoter Regulate Thymocyte Development

DNMT1 silencing induces KIR2DL1/2/3 expression via methylation to alleviate graft-versus-host disease after allogeneic hematopoietic stem cell transplantation

KMT2D Deficiency Impairs Super-Enhancers to Confer a Glycolytic Vulnerability in Lung Cancer

KMT2D mutations promoted tumor progression in diffuse large B-cell lymphoma through altering tumor-induced regulatory T cell trafficking via FBXW7-NOTCH-MYC/TGF-β1 axis

The modification role and tumor association with a methyltransferase: KMT2C

NKG2D Enhances Double-Negative T Cell Regulation of B Cells

KMT2D Mutations Promoted Tumor Progression in Diffuse Large B-cell Lymphoma Through Altering Tumor-Induced Regulatory T Cell Trafficking Via FBXW7-NOTCH-MYC/TGF-81 Axis

METTL3-mediated m6A RNA methylation promotes the anti-tumour immunity of natural killer cells